---
title: Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer
nct_id: NCT01805141
overall_status: COMPLETED
sponsor: Stanford University
study_type: OBSERVATIONAL
primary_condition: Cervical Cancer
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01805141.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01805141"
ct_last_update_post_date: 2018-10-31
last_seen_at: "2026-05-12T06:20:46.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer

**NCT ID:** [NCT01805141](https://clinicaltrials.gov/study/NCT01805141)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 24
- **Lead Sponsor:** Stanford University
- **Conditions:** Cervical Cancer
- **Start Date:** 2013-08
- **Completion Date:** 2018-10-04
- **CT.gov Last Update:** 2018-10-31

## Brief Summary

The investigators hope to learn whether perfusion CT is a useful way to assess primary cervical tumor microenvironment and whether there is a relationship between pretreatment perfusion CT measurements and primary cervical tumor size, lymph node involvement (as assessed by standard of care pretreatment fludeoxyglucose Positron emission tomography/CT (FDG-PET/CT)), and treatment response (as assessed by standard of care 3-month post-therapy FDG-PET/CT).

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion criteria:

* \>18 years old
* with biopsy-proven squamous, adenocarcinoma or adenosquamous cervical cancer
* no history of prior pelvic radiation and should be able to receive chemoradiation
* non-pregnant women who have not previously undergone a hysterectomy, as that would have removed the cervix.
* able to give informed consent

Exclusion criteria:

* Subjects whose tumors are not FDG avid on the pre-therapy PET.
* Allergy or inability to receive iodinated CT contrast
```

## Primary Outcomes

- **Measure perfusion in primary cervical tumors using perfusion CT.** _(time frame: 3-6 months)_ — Treatment response will be assessed using a post-treatment FDG-PET/CT to evaluate for complete response, persistent disease or new disease. The association between pre-treatment perfusion CT parameters and response on the post-treatment FDG-PET/CT will be analyzed.

## Locations (1)

- Stanford University School of Medicine, Stanford, California, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.stanford university school of medicine|stanford|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01805141.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01805141*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*